Kazia Therapeutics Limited – NASDAQ:KZIA
Kazia Therapeutics Limited stock price today
$7.32
+4.25
+138.44%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Kazia Therapeutics Limited stock price monthly change
+242.71%
month
Kazia Therapeutics Limited stock price quarterly change
+242.71%
quarter
Kazia Therapeutics Limited stock price yearly change
+613.95%
year
Kazia Therapeutics Limited key metrics
Market Cap | 10.15M |
Enterprise value | 12.15M |
P/E | -0.95 |
EV/Sales | 1.88 |
EV/EBITDA | -0.95 |
Price/Sales | 3.27 |
Price/Book | 1.82 |
PEG ratio | N/A |
EPS | -2.25 |
Revenue | N/A |
EBITDA | -38.59M |
Income | -37.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -200.35% |
Oper. margin | -557.32% |
Gross margin | 0.01% |
EBIT margin | -557.32% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKazia Therapeutics Limited stock price history
Kazia Therapeutics Limited stock forecast
Kazia Therapeutics Limited financial statements
| Dec 2021 | 10K | -13.20M | -132018.48% |
|---|---|---|---|
| Mar 2022 | 0 | -5.90M | |
| Jun 2022 | 0 | -11.81M | |
| Jun 2023 | 555 | -6.87M | -1239487.03% |
| 2026 | 2.70M | -916.69K | -33.91% |
|---|---|---|---|
| 2027 | 24.17M | 0 |
Analysts Price target
Financials & Ratios estimates
| Jun 2022 | -22761 | -25.01K | 109.91% |
|---|---|---|---|
| Sep 2022 | 0 | 0 | |
| Dec 2022 | 27835603 | 16.25M | 58.39% |
| Jun 2023 | 28085177 | 16.03M | 57.09% |
| Dec 2021 | -11.39M | -278 | 16.7K |
|---|---|---|---|
| Mar 2022 | -5.68M | -391.22K | 1.85M |
| Jun 2022 | -11.37M | -782.45K | 3.70M |
| Jun 2023 | -6.35M | -5.24M | 7.12M |
Kazia Therapeutics Limited alternative data
| Mar 2024 | 9 |
|---|---|
| Apr 2024 | 9 |
| May 2024 | 9 |
| Jun 2024 | 9 |
| Jul 2024 | 9 |
Kazia Therapeutics Limited other data
0.05%
-0.27%
of KZIA is owned by hedge funds
69.01K
-357.13K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2013 | 0 | 3500 |
| Oct 2013 | 0 | 191125 |
| Nov 2013 | 0 | 49322 |
| Insider | Compensation |
|---|---|
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( (1973) Chief Executive Officer, MD & Executive Director | $650,330 |
Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD (1959) Company Sec. | $97,060 |
-
What's the price of Kazia Therapeutics Limited stock today?
One share of Kazia Therapeutics Limited stock can currently be purchased for approximately $7.32.
-
When is Kazia Therapeutics Limited's next earnings date?
Unfortunately, Kazia Therapeutics Limited's (KZIA) next earnings date is currently unknown.
-
Does Kazia Therapeutics Limited pay dividends?
No, Kazia Therapeutics Limited does not pay dividends.
-
How much money does Kazia Therapeutics Limited make?
Kazia Therapeutics Limited has a market capitalization of 10.15M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 415755.86% to 2.31M US dollars.
-
What is Kazia Therapeutics Limited's stock symbol?
Kazia Therapeutics Limited is traded on the NASDAQ under the ticker symbol "KZIA".
-
What is Kazia Therapeutics Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kazia Therapeutics Limited?
Shares of Kazia Therapeutics Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kazia Therapeutics Limited's key executives?
Kazia Therapeutics Limited's management team includes the following people:
- Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( Chief Executive Officer, MD & Executive Director(age: 52, pay: $650,330)
- Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD Company Sec.(age: 66, pay: $97,060)
-
How many employees does Kazia Therapeutics Limited have?
As Jul 2024, Kazia Therapeutics Limited employs 9 workers.
-
When Kazia Therapeutics Limited went public?
Kazia Therapeutics Limited is publicly traded company for more then 26 years since IPO on 6 Jan 1999.
-
What is Kazia Therapeutics Limited's official website?
The official website for Kazia Therapeutics Limited is kaziatherapeutics.com.
-
Where are Kazia Therapeutics Limited's headquarters?
Kazia Therapeutics Limited is headquartered at Three International Towers, Sydney, NSW.
-
How can i contact Kazia Therapeutics Limited?
Kazia Therapeutics Limited's mailing address is Three International Towers, Sydney, NSW and company can be reached via phone at +1 300787272.
Kazia Therapeutics Limited company profile:
Kazia Therapeutics Limited
kaziatherapeutics.comExchange:
NASDAQ
Full time employees:
9
Industry:
Biotechnology
Sector:
Healthcare
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Three International Towers
Sydney, NSW 2000
Sydney, NSW 2000
CIK: 0001075880
ISIN: US48669G1058
CUSIP: 48669G105
